These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35920755)

  • 1. Dermoscopy as response evaluation tool for cutaneous malignant melanoma metastases treated with Talimogene Laherparepvec: a prospective feasibility study.
    Stahlie EHA; van Akkooi ACJ; Plasmeijer E
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2373-2378. PubMed ID: 35920755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC).
    Mulder EEAP; Stahlie EHA; Verver D; Lemstra C; Been LB; Mooyaart AL; Brabander T; Vegt E; Verburg FA; van der Veldt AAM; Verhoef C; van Akkooi ACJ; Grünhagen DJ
    J Surg Oncol; 2021 Dec; 124(7):1161-1165. PubMed ID: 34235758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective.
    Franke V; Stahlie EHA; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    J Immunother; 2022 Jul-Aug 01; 45(6):263-266. PubMed ID: 35580326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
    Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
    Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
    Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
    J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
    Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
    Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talimogene laherparepvec monotherapy for head and neck melanoma patients.
    Franke V; Stahlie EHA; Klop WMC; Zuur CL; Berger DMS; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Melanoma Res; 2023 Feb; 33(1):66-70. PubMed ID: 36454284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difficult to diagnose small cutaneous melanoma metastases mimicking angiomas: utility of dermoscopy.
    Mazzella C; Costa C; Cappello M; Scalvenzi M
    Int J Dermatol; 2018 Sep; 57(9):1085-1087. PubMed ID: 30133751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermoscopy of cutaneous melanoma metastases: A color-based pattern classification.
    Avilés-Izquierdo JA; Ciudad-Blanco C; Sánchez-Herrero A; Mateos-Mayo A; Nieto-Benito LM; Rodríguez-Lomba E
    J Dermatol; 2019 Jul; 46(7):564-569. PubMed ID: 31120139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma.
    Franke V; van der Hiel B; van de Wiel BA; Klop WMC; Ter Meulen S; van Akkooi ACJ
    Eur J Cancer; 2018 Feb; 90():149-152. PubMed ID: 29224902
    [No Abstract]   [Full Text] [Related]  

  • 13. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
    Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.
    Fröhlich A; Hoffmann F; Niebel D; Egger E; Kukuk GM; Toma M; Sirokay J; Bieber T; Landsberg J
    Front Oncol; 2020; 10():611. PubMed ID: 32457834
    [No Abstract]   [Full Text] [Related]  

  • 16. Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma.
    Mulder EEAP; Damman J; Verver D; van der Veldt AAM; Tas S; Khemai-Mehraban T; Heezen KC; Wouters RA; Verhoef C; Verjans GMGM; Langerak AW; Grünhagen DJ; Mooyaart AL
    Melanoma Res; 2022 Aug; 32(4):249-259. PubMed ID: 35446267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
    Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL
    Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.
    Schvartsman G; Perez K; Flynn JE; Myers JN; Tawbi H
    J Immunother Cancer; 2017; 5():45. PubMed ID: 28642816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
    Chitnis SD; Seim NB; Kendra K
    J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.
    van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P
    Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.